Yüklüyor......
Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments
The success of the first approved kinase inhibitor imatinib has spurred great interest in the development of type II inhibitors targeting the inactive DFG-out conformation, wherein the Phe of the DFG motif at the start of the activation loop points into the ATP binding site. Nevertheless, kinase inh...
Kaydedildi:
| Yayımlandı: | Molecules |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6272942/ https://ncbi.nlm.nih.gov/pubmed/27438814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules21070879 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|